Join us on Tuesday, January 12^th for this CME/MOC-accredited webinar
5:00 PM – 6:00 PM ET

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, ImmunoGen Inc and Merck.

Tuesday, January 12, 2021
5:00 PM – 6:00 PM ET
Live CME/MOC-accredited webinar

Topics to Be Discussed

MODULE 1: Management of Ovarian Cancer (OC)

• Guideline-endorsed indications for genetic analysis for patients with newly diagnosed OC; optimal implementation of genetic testing in clinical practice
• Published research from Phase III trials evaluating PARP inhibitor monotherapy as first-line maintenance after platinum-based chemotherapy for advanced OC; benefit in various patient subgroups
• FDA approvals of olaparib and of niraparib as maintenance therapy for patients with newly diagnosed OC; optimal integration into clinical practice
• Key efficacy and safety findings from the Phase III PAOLA-1 trial comparing olaparib/bevacizumab to bevacizumab alone as maintenance therapy for patients with advanced OC who responded to first-line platinum-based chemotherapy and bevacizumab; FDA approval and patient selection for maintenance olaparib/bevacizumab
• Mechanistic rationale for the investigation of veliparib in combination with chemotherapy for OC
• Principal efficacy and safety findings from the Phase III VELIA trial and potential role of veliparib combined with carboplatin/paclitaxel and as continuation maintenance therapy for newly diagnosed OC
• Long-term follow-up and other recently published data sets informing the safe and effective use of PARP inhibitors in the care of patients with platinum-sensitive and platinum-refractory advanced OC
• Published research findings with anti-PD-1/PD-L1 antibodies alone or in combination with other therapies for patients with OC
• Biologic rationale for and ongoing clinical trials evaluating PARP inhibitors in combination with anti-PD-1/PD-L1 agents in the management of OC

MODULE 2: Treatment of Endometrial Cancer (EC) and Cervical Cancer

• Frequency of microsatellite instability (MSI) or mismatch repair (MMR) deficiency in patients with EC
• Available efficacy and safety data with anti-PD-1/PD-L1 antibodies for patients with and without MSI-high (MSI-H) or MMR-deficient (dMMR) EC
• Structural composition and mechanism of action of the anti-PD-1 antibody dostarlimab; documented efficacy in patients with advanced EC and MSI-H/dMMR or microsatellite-stable tumors
• Biologic rationale for combining immune checkpoint inhibitors with chemotherapy for EC; current Phase III trials (eg, RUBY, AtTEnd, DUO-E) evaluating these combinations for patients with recurrent or primary advanced EC
• Key efficacy and safety findings from the Phase II KEYNOTE-146 study assessing lenvatinib in combination with pembrolizumab for patients with relapsed/refractory EC
• FDA approval of lenvatinib/pembrolizumab for patients with advanced EC that is not MSI-H/dMMR who have experienced disease progression after prior systemic therapy; optimal integration into clinical practice

Target Audience
These activities are intended for gynecologic oncologists, medical oncologists, gynecologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of gynecologic cancers.

Learning Objectives
Upon completion of this activity, participants should be able to

• Assess potential biomarkers of response to PARP inhibition to optimize the selection and use of available genetic testing platforms for patients with ovarian cancer (OC).
• Consider the FDA approval of olaparib as maintenance therapy after first-line platinum-based chemotherapy for patients with advanced OC harboring a deleterious or suspected deleterious BRCA germline or somatic mutation, and counsel appropriate individuals regarding personalized treatment recommendations.
• Recognize the recent FDA approval of niraparib as maintenance therapy for advanced OC with or without BRCA mutation in the first-line setting, and identify patients for whom treatment with this agent may be appropriate.
• Evaluate available clinical trial data with olaparib/bevacizumab as first-line maintenance therapy for patients with newly diagnosed OC responding after first-line platinum-taxane chemotherapy with bevacizumab, and use this information to help determine the role of this novel strategy in current clinical practice.
• Appreciate the biologic rationale for and available data with the combination of PARP inhibitors with chemotherapy, and consider the clinical and research implications for OC management.
• Review available data with the use of anti-PD-1/PD-L1 antibodies for microsatellite instability (MSI)-high or microsatellite-stable recurrent endometrial cancer (EC), and appreciate ongoing research attempting to define the therapeutic role of these agents.
• Consider the recent FDA approval of pembrolizumab in combination with lenvatinib for patients with advanced EC that is not MSI high or mismatch repair deficient who have experienced disease progression after prior systemic therapy, in order to optimally integrate this novel regimen into clinical management algorithms.
• Appraise the clinical research supporting the FDA approval of anti-PD-1 monotherapy for progressive PD-L1-positive metastatic cervical cancer, and counsel appropriate patients about the risks and potential benefits of this approach.
• Recognize the incidence of tissue factor expression in patients with cervical and other gynecologic cancers, and consider emerging pivotal research findings and the potential role of tisotumab vedotin for patients with recurrent cervical cancer.
• Recall the design of ongoing clinical trials evaluating novel agents and strategies for gynecologic cancers, and counsel appropriate patients about availability and participation.

CME Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of each CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Dr Coleman — Advisory Committee and Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Genentech, a member of the Roche Group, GlaxoSmithKline, ImmunoGen Inc, Janssen Biotech Inc, Merck, Novocure Inc, Roche Laboratories Inc, Takeda Oncology, Tesaro, A GSK Company; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Genentech, a member of the Roche Group, Janssen Biotech Inc, Merck, Roche Laboratories Inc; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, VBL Therapeutics. Dr Penson — Advisory Committee: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Care4ward (unpaid), Clovis Oncology, Curio Science, Eisai Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Merck, Mersana Therapeutics, NewLink Genetics, Nexus Group Global, Pieris Pharmaceuticals Inc, Roche Laboratories Inc, Sutro Biopharma, Syndax Pharmaceuticals Inc, Tesaro, A GSK Company, Vascular Biogenics; Contracted Research: Array BioPharma Inc, a subsidiary of Pfizer Inc, AstraZeneca Pharmaceuticals LP, Eisai Inc, Genentech, a member of the Roche Group, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Tesaro, A GSK Company, Vascular Biogenics; Data and Safety Monitoring Board/Committee: AbbVie Inc, AstraZeneca Pharmaceuticals LP.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, ImmunoGen Inc and Merck.